• Faculty: Assistant/Associate Member

    Requisition Number 2018-1508
    Department Systems Immunology
  • Overview

    The recently formed Program Center in Systems Immunology at BRI seeks to recruit outstanding applicants for a new faculty position. The appointment will be at the assistant or associate level, commensurate with experience, training, and achievement.

    Systems Immunology is one of four Program Centers at BRI, organized with the mission of using systems approaches to elucidate fundamental mechanisms, new biomarkers and therapeutic targets in immune diseases. We seek candidates who will use systems and/or computational approaches to study the functioning of the immune system in health and disease, with a particular emphasis on autoimmune diseases, allergy and/or cancer.


    Ideal candidates will combine genomic (RNA and/or DNA), multidimensional cytometry and functional measurements into multidimensional computational models of immune function that predict progression and/or response to therapy in immune disease settings. The BRI Systems Immunology Program Center offers state of the art computing, laboratory and animal facilities for research, as well as access to excellent Genomics Core and Bioinformatics groups.

    About BRI

    BRI is an international leader in autoimmune disease research translating discoveries to real life applications. BRI is one of the few research institutes in the world devoted to finding causes and cures for immune system diseases that include type 1 diabetes, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, allergies and asthma. BRI maintains an extensive biorepository with samples dating back decades in multiple disease categories, as well as a biorepository of people without autoimmune diseases for comparison purposes.

    About the position

    A key feature of this position is the exceptional collaborative opportunities it offers. BRI provides a highly interactive environment, linking individual investigators in basic and translational immunology with systems and computational expertise. Housed within BRI are two international clinical research networks providing additional opportunities for translational research: the Immune Tolerance Network (ITN,) a collaborative network for clinical research focused on the development of therapeutic approaches that lead to immune tolerance; and Type 1 Diabetes (T1D) TrialNet, an international network that conducts clinical studies in T1D. The Seattle area also offers a rich and historically collaborative academic environment, with multiple major Universities, Research Institutions, Hospitals, and Biotechnology/Pharma and Software companies located in close proximity.


    The ideal candidate will be an early stage investigator holding a PhD and/or MD degree; having significant research experience in systems and/or computation biology; and subject matter familiarity with a biological field, ideally immunology. The successful candidate must have an exceptional track record in his/her chosen field, preferably using systems approaches to fundamental and/or translational problems in immunology. He/she should also have a track record or strong potential for obtaining research funding from national and international research agencies. The successful candidate will be expected to maintain an active research program, contribute to the research environment at BRI, collaborate closely with researchers working at BRI, and maintain a network of external collaborators in Seattle and internationally. 


    All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, citizenship, disability or protected veteran status.

    Contact information

    Qualified candidates should send inquiries, or an application package comprising their curriculum vitae, a letter explaining their motivation, research interests and qualifications, and names of three references to SIRecruit@benaroyaresearch.org.


    Sorry the Share function is not working properly at this moment. Please refresh the page and try again later.
    Share on your newsfeed